Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2007

View Archived Issues

Positive preclinical results with a combined hepatitis A and E vaccine

Active end to 2006 for Gilead Sciences

T-2000 improves essential tremor in two small studies

Safety and efficacy of a transdermal Alzheimer's Abeta/CT vaccine shown in mice

Promising preclinical results with Domantis domain antibodies against vaginal candidiasis

Lonafarnib to enter clinic for the treatment of progeria syndromes

SIR-Spheres, bevacizumab + chemotherapy studied for metastatic colorectal cancer

Wyeth welcomes decision to fund pneumococcal vaccine for developing countries

Recent patents cover therapeutic agents for cardiovascular disorders

Novel treatment options for HCV infection reported in recent patents

Recent Bayer and AiCuris patents disclose new antiinfective agents

GSK commends pneumococcal vaccine advance market commitment

PEP-005 Topical studied in phase II trial for superficial BCC

Cytyc to acquire Adeza

Micromet exercises option for Morphotek antibody

Ariad grants commercial license to Argent technology to CellNexus

Ambrx studies next-generation human growth hormone product in phase I/II study

Adolor studies novel delta opioid receptor agonists

Avant and Select Vaccines to develop improved viral vaccines

Fast track designation for BioThrax for anthrax post-exposure prophylaxis

Biovail to use Depomed's AcuForm technology

Findings made available from Diabetes Genetics Initiative

Revisions to U.S. prescribing information for Ketek

Interim data support improvements in inflammatory arthritis with tgAAC94

Ono updates recent developments

Accelerated reviews for maraviroc

Recent Pfizer patent discloses novel therapeutic agents for gastrointestinal disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026